New pivotal trial data suggest AstraZeneca will soon be able to compete with PD-1/L1 inhibitor leaders in early-stage non-small cell lung cancer (NSCLC) treatment, but whether its perioperative approach of drug treatment before and after surgery will outshine rivals is yet to be seen.
The company has just unveiled the positive high-level results from a planned interim analysis from the AEGEAN study, which tested...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?